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ABSTRACT: The position effect variegation in Drosophila and 
Schizosaccharomyces pombe, and higher-order chromatin 
structure regulation in yeast, is orchestrated by modifier genes of 
the Su(var) group, (e.g., histone deacetylases ([HDACs]), protein 
phosphatases) and enhancer E(Var) group (e.g., ATP [adenosine 
5-triphosphate]-dependent nucleosome remodeling proteins). 
Higher-order chromatin structure is regulated in part by covalent 
modification of the N-terminal histone tails of chromatin, and 
histone tails in turn serve as platforms for recruitment of 
signaling modules that include nonhistone proteins such as 
heterochromatin protein (HP1) and NuRD. Because the enzymes 
governing chromatin structure through covalent modifications of 
histones (acetylation, methylation, phosphorylation, 
ubiquitination) can also target nonhistone substrates, a 
mechanism is in place by which epigenetic regulatory processes 
can affect the function of these alternate substrates. The 
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posttranslational modification of histones, through 
phosphorylation and acetylation at specific residues, alters 
chromatin structure in an orchestrated manner in response to 
specific signals and is considered the basis of a “histone code.” In 
an analogous manner, specific residues within transcription 
factors form a signaling module within the transcription factor to 
determine genetic target specificity and cellular fate. The 
architecture of these signaling cascades in transcription factors 
(SCITs) are poorly understood. The regulation of estrogen 
receptor (ER) by enzymes that convey epigenetic signals is 
carefully orchestrated and is reviewed here.  
 
 
EPIGENETICS  
Epigenomics refers to the study of heritable changes in gene 
expression that occur without a change in DNA sequence. 
Through the silencing of tumor suppressor genes, epigenetic gene 
regulation frequently plays a critical role in the pathogenesis of 
cancer. Epigenomic modifications include covalent modifications 
of DNA and histones as well as noncovalent changes regulating 
nucleosome positioning. The enzymes regulating epigenetic 
change have been characterized in a number of animal systems 
including Drosophila and transgenic mice. Recent studies have 
characterized the mammalian enzymes that regulate epigenetic 
change. Environmental factors including hormones in turn 
regulate activities of several enzymes, altering DNA methylation 
and histone acetylation patterns.  
Histone Methylation  
Several recent studies have demonstrated the importance of 
histone methylases and histone demethylases in regulating 
estrogen receptor (ER) activity and expression. Posttranslational 
modification that does not alter DNA sequence requiring 
methylation occurs both on DNA and on proteins. Methylation of 
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chromatin is often linked to methylation of DNA. A number of 
histone methylating enzymes directly interact with DNA 
methylating enzymes (DNA methytransferases (DNMTs) and 
methyl-binding proteins).1 Modification by methylation of DNA 
is generally targeted to cytosine residues in CpG dinucleotide 
pairs. Methylation governs genomic stability, retroelement 
suppression, and gene promoter regulation. Regions of CpG in 
the mammalian genome include large CpG islands (>500 bp), 
small CpG islands (200–500 bp) associated with transposons, and 
nonisland CpGs. DNA methyltransferases are associated with the 
replication complex in mammalian cells. This finding is 
consistent with a model in which the signals for methylating 
sequences in the genome are provided by a pre-existing 
hemimethylation. Thus, replication of the sequence to daughter 
chromatids temporarily results in hemimethylated DNA, which is 
recognized by DNMTs, ensures restoration of the symmetrical 
methylation of both DNA strands. The other major signal for 
methylation in mammalian cells is the presence of SINE 
elements.
36  
 
Methylation of histones occurs on either lysine or alanine 
residues, resulting in either condensation or relaxation of the 
chromatin architecture. Methylation likely provides binding sites 
for regulatory proteins with specialized binding domains. The 
main sites of methylation of histones occur on either 
heterochromatin or euchromatin. Heterochromatin is condensed 
and considered transcriptionally silent, whereas euchromatin is 
less densely packed and transcriptionally active. Methylated 
lysine residues are located characteristically within 
heterochromatin and demarcate subdomains.
1 
Methylated histone 
residues serve as docking sites for repressive proteins, including 
the polycomb protein (PC) and heterochromatin protein (HP1), 
which recognize histone H3, K27 or H3, K9, respectively. HP1 
and PC recognize methylated lysine residues through their 
chromo domain. Other proteins recognize methylated lysine 
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residues though two other motifs, known as the Tudor domain 
and the WD40 repeat domain.  
 
Histone methylation by protein arginine methyltransferases 
represents a relatively prevalent modification of proteins. The 
protein arginine methyl transferases (PRMTs) consist of two 
types, differing in the asymmetry of the dimethylarginine, 
product. The Type 1 PRMT forms monomethylarginine and 
asymmetric dimethylarginine, whereas Type 2 PRMT forms 
monomethylarginine and symmetric dimethylarginine. The 
PRMTs, 1, 2, 3, 4, and 6 are Type 1 PRMTs. The Type 2 PRMT 
is represented by PRMT5, also known as CARM1 (coactivator-
associated arginine methyltransferase). Stallcup and coworkers4 
demonstrated that CARM1 encodes both an arginine 
methyltransferase and a nuclear receptor coactivator, linking 
posttranslational modification by methylation to ER receptor 
signaling.  
 
The histone lysine methylases share a common SET (Su/var, 
Enhancer of Zeste, Trithorax) domain. The SET domain conveys 
the S-adenosyl-Lmethionine cofactor to the epsilon amino group 
of the lysine residues. The histone H3 lysine 9 methyltransferase 
group catalyzes H3, lysine 9 methylation and includes Suv39h1, 
Suv39 h2, G9a, G9a-related protein and the SET DB1 gene 
products.  
 
Enzymatic demethylation of histone was first described in 1973 
by Paik and Kim.
37 
The identification of specific proteins 
regulating this activity took many years to be identified, however. 
Recently several lysine specific demethylases have been 
described, including lysine specific demethylase 1 (LSD1), 
JHDM1, JHDM2A, and JMJD2.
32  
 
In addition to removal of arginine methylation by lysine 
demethylases, the methyl group can be removed from the 
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arginine by the conversion of the methylarginine residue into 
citrulline, referred to as deimination. Deimination is conducted 
by arginine peptidyl arginine deiminase 4 (PADI4), which 
converts unmodified arginine and monomethylated arginine to 
citrulline at specific sites on the tails of H3 and H4.
6 
Importantly, 
for the purpose of this review, PADI4 repressed the estrogen-
regulated gene, pS2, linking arginine demethylation to ER 
signaling.  
Histone Acetyltransferases and Deacetylases  
ER function can be regulated by histone acetylases and histone 
deacetylases (HDACs). Euchromatic DNA is packaged by 
histones into nucleosomes composed of 147 base pairs of DNA 
and the core histone proteins (H2A, H2B, H3, and H4). Dramatic 
alterations in chromatin structure are modulated through 
posttranslational modification of lysine tails.
9 
Conserved lysine 
residues are present in the amino terminal tails of all four core 
histones. Acetylation of lysine residues is thought to both 
neutralize the basic charge of histone tails and to serve as 
epigenetic markers which provide recognition motifs for docking 
of proteins that recruit transcriptional activators or repressors. 
The histone acetyl-transferase (HAT) enzymes were historically 
described as Type A, located in the nucleus, and Type B, located 
in the cytoplasm. Type B typically have a housekeeping role, 
acetylating newly synthesized free histones, whereas Type A 
HAT acetylate nucleosomal histones within chromatin in the 
nucleus. The Type A nuclear HATs include five families, the 
Gcn5-related acetyltransferases (GNATs), the MYST (MOZ, 
Ybf2/Sas3, Sas2, and Tip60)-related HATs, the HATs regulating 
general transcription (TAFII250), the CBP/p300 cointegrator 
HATs; and the p160 coactivator HATs, (SRC-1 and SRC3).9   
 
The dynamic remodeling of acetylated lysine residues is 
mediated through two distinct types of HDACs: trichostatin A 
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(TSA)-sensitive and NAD-regulated. TSA-sensitive HDACs 
include the class 1 HDACs (HDACs 1, 2, 3, and 8) which are 
related to the Saccharomyces cerevisiae transcriptional regulator 
RPD3. The class II HDACs are related to the yeast HDA1 protein 
and include HDACs 4, 5, 6, 7, 9, and 10. HDAC 11 is more 
related to the Type 1 HDACs and contains a catalytic domain at 
the N-terminus with HDAC activity.  
NUCLEAR RECEPTORS  
Nuclear receptors function as transcription factors that govern 
transcription of genes. Their activity can be regulated by steroids, 
thyroid hormone, retinoic acids, or vitamins, and they coordinate 
diverse processes such as homeostasis, reproduction, 
development, metabolism, and disease.
40 
There are four main 
conserved domains of all nuclear receptors. These domains 
include the activation function domain (AF), the DNA-binding 
domain (DBD), the hinge region, and the ligand-binding domain 
(LBD), the latter being the site of many protein–protein and 
hormone interactions.  
 
Coregulator proteins, both coactivators and corepressors, work 
with nuclear receptors in complexes that govern gene expression. 
Nuclear receptors and the transcriptional apparatus are often 
linked together through coactivator recruitment of protein 
complexes. These complexes then can use their histone-
modifying abilities to alter the local chromatin structure. Several 
coactivators that bind to nuclear receptors include steroid 
receptor coactivator-1 (SRC-1), amplified in breast 
cancer1/thyroid and RA receptor/SRC-2 (AIB1/ACTR/SRC-2), 
glucocorticoid receptor interacting protein 1/transcriptional 
intermediary factor 2/SRC-3 (GRIP1/TIF-2/SRC3), menin, and 
p300/CBP and p300/CBP-associated factor (p/CAF).17,18,51 
Corepressors function with unliganded nuclear receptors to 
silence gene expression. These corepressors include proteins like 
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nuclear receptor corepressor (N-CoR), silencing mediator of 
retinoid and thyroid hormone receptor (SMRT), Sin3, HDACs, 
thyroid hormone receptor uncoupling protein (TRUP), BRCA1, 
NuRD, Suv39h1, DNMT1, pRB2/p130, and E2F4/5.
17,18,51  
 
 
THE ESTROGEN RECEPTOR 
 
The last two decades have seen an evolving body of literature 
providing a compelling case for dynamic regulation of ER 
function through both posttranslational modification by 
acetylation and through epigenetic signaling cascades. The 
nuclear receptor, ER, is activated by, and controls the activity of, 
the steroid hormone, estrogen. Together estrogen and its receptor 
are vitally important in normal development, reproduction, and 
various diseases. ER is distributed at the cellular membrane, the 
cytoplasm, the nucleus, and the mitochondria. The membrane-
bound form of ER regulates nongenomic function through 
interactions with SHC and caveolin-1, inducing acute activation 
of PI3 kinase and Akt signaling pathway. The nuclear form 
provides DNA-dependent regulation of gene expression. 
Epigenetic regulation has been well characterized for the nuclear 
located ER. The role of epigenetic signals of ER located in other 
compartments of the cell remains to be better understood.  
 
ER binds DNA either directly or through other transcription 
factors (AP-1, Sp1) in order to regulate transcription of target 
genes. The ER functional activity in the nucleus is mediated 
through binding of coactivator and corepressors, which encode 
enzymes with HAT-modulating activity. The cointegrators 
CBP/p300 (CREB-binding factor) encode intrinsic HAT activity. 
The binding of HATs to the ER provides a docking function 
leading to acetylation of local histones with consequent 
nucleosomal destabilization facilitating transcription factor 
binding to local DNA sequences at promoter regions of estrogen-
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responsive genes. Some proteins that are already known to bind 
the ER include members of the p160 family (SRC-1, 
TIF2/GRIP1/SRC-2, AIB1/ACTR/SRC-3), cyclin D1, menin, 
and many HATs (CBP, p300, p/CAF).21,29,30 The p160 coactivator 
family (SRC1/amplified in breast cancer/activator of the thyroid 
and RA receptor/ SRC-2 to [AIB1/ACTR/SRC3]) and the related 
group 1 (GRIP-1/TIP-2/SRC-2) facilitate the interaction between 
the p300 coactivator and the nuclear receptor. In addition, nuclear 
receptor repressors of the N-CoR and SMRT complex physically 
associate with the ER particularly in the presence of the ER 
ligand antagonists such as tamoxifen. The ER has been shown to 
physically associate with several corepressors which encode 
intrinsic HDAC activities including BRCA1 and MTA1.
8 
BRCA1 
binds the ER to repress ligand-induced gene expression. BRCA1 
repression of ER is opposed by endogenous cyclin D1 through 
physical association within local chromatin
45 (FIG. 1). It is 
plausible that BRCA1 association with ER may play a role in the 
recently described finding that transient double-stranded DNA 
break formation occurs during ER ligand-dependent gene 
transcription.
24 
 
Epigenetic Modifiers Silence the ER Gene  
In breast cancer ER gene expression is an important prognostic 
factor.
52 
Altered expression and function of ER coregulators with 
epigenetic function have been demonstrated to play a role in 
hormone signaling. The AIB1 protein is frequently amplified in 
breast cancer correlating with the ER-positive status.
2 
The 
expression levels of TIP2, CBP, and ER are strongly correlated in 
intraductal breast carcinomas.
31 
Furthermore, tamoxifen-resistant 
tumors show a shorter relapse of survival in samples with low 
expression of NCoR.
20  
 
Unfortunately though, 30% of breast cancers are ER-negative 
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upon diagnosis
22 
and many breast cancers can lose ER expression 
during progression of the cancer. In many patients epigenetic 
modification plays a role in the loss of ER gene expression. Yang 
et al.
54 
demonstrate reduced ER expression due to increased DNA 
methylation and/or histone deacetylation.
54 
The demethylase 
PADI4 has been linked to the repression of the estrogen-
responsive gene pS2.
6 
HDACs bind ER and HDAC 
overexpression silences expression of the ER gene.
25 
siRNA-
mediated reduction of DNMT1 induced ER expression.
39,53 
Two 
commonly used inhibitors of this silencing mechanism are the 
DNMT inhibitor, 5-aza-2-deoxycytidine (5-aza-dC), and the 
HDAC inhibitor, TSA. Treatment with either inhibitor 
individually enhanced ER gene expression.
25,54,55 
Use of both 5-
aza-dC and TSA enhanced re-expression of both ER mRNA and 
protein in human breast cancer cells. The re-expressed ER was 
functional and it induced expression of known ER target genes. 
Collectively these studies suggest how inhibitors of HDACs and 
DNMTs may be used to reinduce ER expression and thereby 
restore therapeutic response to ER antagonists.  
 
Macaluso et al.
34 
examined further the mechanisms silencing 
the ER gene and identified several multimolecular ER repression 
complexes. pRb2/p130E2F4/5-HDAC1-SUV39H1-p300 or 
pRB2/p130-E3F4/5-HDAC1-DNMT1SUV39H1 proteins were 
found on the ER promoter. These complexes included HDACs, 
DNMTs, the histone methyltransferase, SUV39H1, and the cell 
cycle regulatory protein, pRb2/p130. It was hypothesized that 
protein complexes recruited by pRb2/p130 modulate acetylation 
or methylation to the ER promoter, regulating its expression by 
altering the local chromatin structure through the histone 
methyltransferases, like SUV39H1. Sharma et al.
42 
examined the 
multimolecular protein complexes upon treatment of cells with 5-
aza-dC and TSA. Cells with silenced ER demonstrated DNA 
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hypermethylation, histone hypoacetylation, H3K9 methylation, 
and an increased abundance of methyl-binding proteins, DNMTs, 
and HDACs. Treatment of these cells with the HDAC and 
DNMT inhibitors led to ER re-expression, release of the 
repressor complexes, enrichment of histone acetylation, and 
decreased H3K9 methylation.  
 
 
 
The ER Works in Regulating Target Gene Transcription with 
Coregulators 
 
In addition to the HATs and HDAC-containing complexes, ER 
forms protein complexes with other coregulatory proteins to 
govern expression of genes.  
 
A component of a histone methyltransferase complex regulates 
the ER to further regulate target genes.
7 
Menin is the protein 
product of the multiple endocrine neoplasia 1 (MEN1) tumor 
suppressor gene. It is a component of the MLL1/MLL2 H3K4 
histone methyltransferase complex, which is typically linked to 
gene activation. Menin physically associates with the ER and 
works as a coactivator to activate the expression of the ER target 
gene, pS2 (TFF1).7 Importantly, MEN1 mutations associated with 
disease disrupted any ER-menin interaction and the ER activity.  
Acetylation of the ER Regulates its Activity  
In the first studies demonstrating direct acetylation, the ER was 
shown to be acetylated in MCF7 human breast cancer cells by 
immunoprecipitation Western blotting.
44 
GST-fusion proteins of 
the ER were then shown to serve as in vitro substrates for 
acetylation in the presence of p300, produced in baculovirus. 
______________________________ 
This article has been peer reviewed.  It is the authors' final version prior to publication in Annals 
of the New York Academy of Sciences 1089:73-87, November 2006.  The definitive version is 
available at http://www.blackwell-synergy.com/doi/abs/10.1196/annals.1386.047. 
Deletion analysis identified a minimal region of ER acetylated by 
p300. Edman degradation assays and MALDI-TOF mass 
spectrometry identified the acetylated residues as preferentially 
lysine K302 and K303 with some minimal acetylation of lysine 
299. A minimal ER peptide was acetylated by p300 with similar 
efficiency as histone H3. Point mutations of the lysine residues in 
ER resulted in ER mutants that were activated at lower 
concentrations of E2 than the wild-type ER. Glutamine or alanine 
substitutions of the acetylated lysine residues enhanced 
transactivation; in particular, ER activation by p300 was 
enhanced. The alteration in transactivation by the acetylation site 
was distinct and did not affect activation by other kinases, 
including mitogen-activated protein kinase or activation by the 
p68 RNA helicase A.
44 
The ER K303R mutation conferred 
enhanced activation of ER activity at low subphysiological levels 
of hormone. The ER lysine motif that was acetylated directly by 
p300 was shown to be conserved across species and the motif 
was identified in many other phylogenetically related receptors, 
including the androgen receptor and PPAR
44 (FIG. 2). Analysis of 
the related lysine motif in the AR demonstrated a similar 
biochemical function and growth-regulatory properties.
11,14–16  
 
Independently of these findings another laboratory had 
identified a point mutation of the ER at K303 occurring as a 
somatic mutation in human breast cancer.
19 
The mutation of 
K303 occurred with high frequency (30%) of early breast cancer 
lesions, referred to as ductal carcinoma in situ. The ERK303R 
mutant conveyed a growth advantage to breast carcinoma cells in 
culture.
19 
Growth assays demonstrated that the acetylation site 
ERK303R mutation enhanced cellular proliferation in response to 
low concentrations of estradiol, suggesting the ER K303R 
mutation provides a “gain of function” mutation in human breast 
cancer.  
 
Analysis of other nonhistone substrates for acetylation, such as 
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p53, provides evidence that the acetylation of transcription 
factors may in turn regulate their phosphorylation
28 
by distinct 
kinases.
28 
Thus, acetylation of lysine 320 prevents 
phosphorylation of serine in the NH2-terminal region of p53. The 
ER is phosphorylated by protein kinase A at residue 305. The 
generation of a kinase-active mutant of the ER through the 
introduction of an aspartic acid residue blocked acetylation of the 
ER.
5 
Studies by Cui et al. demonstrating ER acetylation is linked 
to phosphorylation of the ER at residue serine 305 may be of 
importance to therapy resistance in breast cancer, as PKA 
activation of ER has been linked to tamoxifen resistance.
35 
These 
studies suggesting that acetylation and phosphorylation within 
the ER are coupled are consistent with prior studies coupling 
acetylation and phosporylation of the androgen receptor.
11,50  
 
p53 is known to be acetylated at distinct sites coordinating 
distinct signaling pathways.
28 
It is known that p300/CBP 
acetylates carboxyl-terminal lysine residues of p53 (lysines 372, 
373, 382). P/CAF acetylates a residue within the flexible linker 
region of p53 (lysine 320). In response to genotoxic stress, DNA 
damage induces acetylation of lysine 320 and lysine 373 with 
distinguishable kinetics. These two distinct acetylation sites 
regulate distinct clusters of genes with high-affinity p53-binding 
sites, promoting cell survival.
28 
In contrast K373 regulates 
interactions with affinity DNA-binding sites found in 
proapoptotic genes leading to cell death. In keeping with the 
finding of multiple modular acetylation sites in p53, additional 
acetylation sites were identified in the ER at lysine K266 and 
K268.
27 
Contrary to K302/303, which were acetylated directly by 
p300,
44 
K266/268 was acetylated in an assay using p300/p160 
(SRC1) and the ligand estradiol.  
 
Although the distinguishable biological functions of the ER 
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lysine residues remains to be determined, the acetylated residues 
in the androgen receptor (K302/303) promote DNA synthesis and 
antiapoptotic signals.
11,14–16 
The AR acetylated residues regulate 
access to DNA in chromatin immune precipitation assays
11 
and 
promote binding to promoters of target genes that induce DNA 
synthesis such as cyclin D1.
11,14–16 
The p53 acetylation site also 
alters access within the local chromatin structure to enhance 
DNA binding.
28 
In electrophoretic mobility shift assays, the ER 
acetylation (K266, and K268) was shown to regulate DNA 
binding, whereas acetylation of the ERK303 site does not affect 
binding. The application of an unbiased proteomic approach to 
examine ER residues acetylated in vivo under physiological 
conditions and in tumors will be of interest (FIG. 3).  
Cyclin D1 Regulates ER Activity  
The cyclin D1 gene product is overexpressed in 30–40% of 
cancers and is associated with poor prognosis in ER-positive 
breast cancer patients.
26,38 
Initially cloned as part of a breakpoint 
rearrangement in parathyroid adenoma, the cyclin D1 protein has 
subsequently been shown to bind HDACs, the pRB protein, and 
several transcription factors.
13 
Cyclin D1 contributes a catalytic 
subunit function of a kinase that phosphorylates pRb and 
NRF1.
41,47 
Phosphorylation of pRB in the nucleus regulates DNA 
synthesis, while phosphorylation of NRF1 regulates 
mitochondrial biosynthesis.
41,47 
At the membrane, cyclin D1 
promotes cellular migration, and angiogenesis through induction 
of cytokines and vascular growth regulatory proteins (VEGF, 
TSP1).33  
 
The role of cyclin D1 in regulating the nuclear receptor is 
complex. In vivo, cyclin D1 knockout mice develop a phenotype 
of enhanced PPAR activity with hepatic steatosis due to the 
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inhibition of PPAR activity by cyclin D1.
48 
Cyclin D1 has been 
shown to associate with the ER and enhance ER activity, in part 
through recruiting the SRC1 p160 coactivator in a ligand-
independent manner,
56 
and also through antagonizing the ER 
corepressor BRCA1.
43 
Cyclin D1 functions in regulating both ER 
and BRCA1 occupancy in the context of local chromatin at an 
estrogen response element of the pS2 gene.
43 
The finding that 
cyclin D1 regulates local chromatin occupancy is consistent with 
the findings that cyclin D1 binds SUV39, HP1 and HDACs and 
that the abundance of cyclin D1 determines the local acetylation 
of histones, including histone H3 Lys9.
10,23,46 
It is known that 
mammary-targeted expression of cyclin D1 induces mammary 
tumorigenesis in transgenic mice. Therefore, it will be of interest 
to determine the relative importance of these kinase-independent 
functions of cyclin D1 in inducing mammary tumorigenesis and 
estrogen responsiveness.  
CONCLUSIONS  
Over the last decade histone-modifying enzymes have been 
successfully cloned and characterized. These posttranslational 
modifications within histone tails provide the basis of signaling 
modules within the local chromatin, known as the “histone code.” 
Recent studies have demonstrated the presence of similar enzyme 
complexes associated with the ER. Similar to histone tails, 
transcription factors, such as p53 and the nuclear receptors, 
ERand the AR, encode signaling modules within the protein, in 
which one posttranslational modification leads to a sequential 
commitment to other types of posttranslational modifications. 
Cascades of acetylation, phosphorylation, and ubiquitination 
modify the receptors’ function, genetic response, and consequent 
cell fate decisions. Although these signaling cascades in 
transcription factor or SCITs are poorly understood at this time, 
the residues for posttranslational modification appear to be well 
conserved across species. In the same manner that cytoplasmic 
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signaling cascades in the last decades defined kinase modules, so 
too will the next decade provide important insights into 
intratranscription factor signaling cascades that may ultimately 
contribute to the biological specificity of nuclear receptor 
signaling.  
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FIGURES 
 
 
 
 
 
FIGURE 1. Hypothetical model by which cyclin D1 augments 
ER  signaling. The ER activity is repressed by BRCA1,
8 
Endogenous cyclin D1 opposes the action of BRCA1 at an 
ERE. Cyclin D1 associates directly with the ER The prevailing 
view in cancer biology is that two general classes of cancer 
genes exist, those that regulate genomic stability including 
antimutators and DNA repair genes, and a second class of 
genes regulating cell cycle control. Cyclin D1 shares both 
properties, promoting DNA synthesis and regulating the 
function of BRCA1.
43 
Estradiol induces BRCA1 to the pS2 
ERE in ChIP assays, an effect antagonized by cyclin D1,
43 
and 
E2 induces transient double-strand breaks with the recruitment 
of DNA repair complexes to the ERE of the pS2 gene. 
Collectively these studies support a model in which cyclin D1 
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regulates both cell proliferation and DNA repair function.  
 
 
 
FIGURE 2. Phylogenetic conservation of the acetylation 
motif. The phylogenetic tree linking nuclear receptors in 
vertebrate arthropods and nematodes is shown. Nuclear receptors 
containing the acetylation motif are shown in yellow, whereas 
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nuclear receptors lacking the motif are shown in pink.
49  
 
 
 
 
FIGURE 3. The ER is regulated by TSA and NAD-dependent 
HDACs. The ER and the AR are acetylated at conserved lysine 
residues. Although NAD regulates ER activity, p300, an essential 
coactivator of ER, is also repressed by Sirt1.
3 
The AR has been 
shown to be directly regulated by acetylation in response to 
physiological stimuli and to be repressed by SIRT1 in a catalytic 
domain-dependent manner.
12 
An acetylated AR substrate 
functions as an excellent substrate for SIRT1. The nuclear 
receptor acetylation site governs nuclear receptor function, as 
indicated to the right, including transactivation DNA synthesis 
and apoptosis. In the case of the AR, the transrepression and 
sumoylation of the AR are unaffected by acetylation. 
 
 
